Prof Sir Marc Feldmann, AC FAA FRS FRCP FRCPath FMedSci is a preeminent immunologist, and a Prof at the University of Oxford. After graduating with an MBBS degree from the University of Melbourne in 1967, he earned a Ph.D. in Immunology at the Walter and Eliza Hall Institute of Medical Research in 1972 with Sir Gustav Nossal. Prof Sir Marc Feldmann undertook postdoctoral research (1972) at the Imperial Cancer Research Fund’s Tumour Immunology Unit with Prof Avrion Mitchison, which led to the generation (1983) of a new hypothesis for the mechanism of autoimmunity. Testing this idea led him to leave ICRF and move to the Charing Cross Sunley Research Centre in 1985, which merged with the Kennedy Institute of Rheumatology. This then joined with the Faculty of Medicine at Imperial College in 2000. In August 2011, the Kennedy Institute of Rheumatology transferred to the University of Oxford. In 1983, he published a new hypothesis for the mechanism of induction of autoimmune diseases, highlighting the role of cytokines. Cytokines are potent signalling proteins, local hormones, which drive important processes like inflammation, immunity and cell growth. In collaboration with Ravinder N. Maini at the Kennedy Institute of Rheumatology they demonstrated that diseased joints have excessive Tumour Necrosis Factor Alpha and with the help of Dr F Brennan, TNF was defined as a therapeutic target for RA since blocking it in cultures of human arthritic joint tissue or in arthritic mice had profound beneficial effects.
Prof Sir Marc Feldmann’s research has led to his recognition as a pioneer in immunology. He is Fellow of the Royal College of Physicians and of the Royal College of Pathologists. He was elected a Fellow of multiple national Academies, the Academy of Medical Sciences and the Royal Society in London, the Australian Academy of Science, and he is a Foreign Member of the National Academy of Sciences, USA. He was knighted in the 2010 Queen’s Birthday Honour for his outstanding services to medicine.
Along with Dr. Maini, Dr. Feldman was awarded the Crafoord Prize “for identification of TNF blockade as an effective therapeutic principle in rheumatoid arthritis, In 2003, the two were awarded the Albert Lasker Award for Clinical Medical Research for “discovery of anti-TNF therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases”. In 2004, the Cameron Prize for Therapeutics of University of Edinburgh. In 2007, Feldmann was awarded The European Patent Offices “European Inventor of the Year” in the Lifetime Achievement Category, the first award made in medicine. In 2008 he was awarded the Dr. Paul Janssen Award for Biomedical Research together with Maini. He was awarded the John Curtin Medal of the Australian National University in 2007. Feldmann and Maini were awarded the Ernst Schering Prize in Germany in 2010, and the Canada Gairdner International Award in 2014. Prof Sir Marc Feldmann is an Emeritus Prof at the Kennedy Institute of Rheumatology, Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences in the University of Oxford. Centocor licensed Feldmann and Maini’s key patent, and then developed Infliximab, ultimately branded as Remicade. Remicade was the main driver of the $4.9B USD acquisition of Centocor by Johnson and Johnson and is the 4th highest selling drug in the word, reaching over $8 Billion USD in sales in 2018. Prof Sir Marc Feldmann is an expert in the development of anti-inflammatory therapeutics. Anti-TNF therapeutics which they pioneered are since 2012 the most profitable Pharmaceutical drug class with sales in 2016 that exceeded $36B USD.
Prof Sir Marc Feldmann has authored over 600 published papers reflecting an overarching commitment to both the cellular aspects of inflammatory autoimmune biology messenger molecules, cytokines and therapeutic applications.
Jagdeep is a surgeon scientist and Prof at the University of Oxford, focusing on defining the molecular mechanisms of common diseases and translating his findings through to early phase clinical trials. He undertook his PhD, funded by the MRC, whilst a medical student in London. His surgical background coupled with state-of-the-art molecular biological techniques has allowed him to bring a unique insight to common, yet relatively neglected diseases and many of his findings stem from investigations in primary human tissues, rather than relying on animal models that often fail to recapitulate all the facets of the clinical condition. His research focussed on promoting tissue regeneration by targeting endogenous stem cells and reducing fibrosis.
In 2013 his group identified TNF as therapeutic target for Dupuytren’s disease, a common fibrotic condition of the hand. He recently published the data from a phase 2a clinical trial based on a novel design whereby an effective dose and preparation of anti-TNF was identified based on molecular markers of human tissue. He is now leading the phase 2b/3 trial funded by the Wellcome Trust and UK Department of Health. His work on complex fractures has led to the identification of a highly conserved physiological pathway whereby a protein released by damaged cells accelerates repair and regeneration of multiple tissues. Administration of only a single dose of the protein is effective across a range of disorders by targeting the body’s own stem cells.
Prof Chas Bountra an expert in pharmaceutical clinical development, and pain, was previously Vice President and Head of Biology at GlaxoSmithKline for 20 years. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. More than 20 of these molecules progressed into patient studies and more than five of these delivered successful “Proof of Concept” data and progressed into late stage development. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are antiemetic in preclinical and clinical studies. He is also a Visiting Prof in Neuroscience and Mental Health at Imperial College, London. Prof Chas Bountra is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and drug discovery programmes.
Prof Chas Bountra is currently Prof of Translational Medicine at the Nuffield Department of Medicine, Head of the Structural Genomics Consortium (SGC) and an Associate Head for the Medical Sciences Division, at the University of Oxford. From October he will also be the Pro Vice Chancellor for Innovation in the University of Oxford. He has more than two decades of academic and industrial experience in target identification, lead discovery, lead optimisation, and designing phase II and III studies in several neuro-psychiatric, gastrointestinal and inflammatory conditions. He has now established the SGC as a world leading outfit for human protein structural biology and the chemical biology of epigenetics. Prof Chas Bountra was voted one of the top innovators in the Pharmaceutical industry in 2012. Prof Chas Bountra has received multiple awards such as the Top innovator award from Pharmaphorum, the Rita and John Cornforth award from the Royal Society of Chemistry, the Best Public Private Partnership award, from Oxford Biotech Network and the Master of the Bench award from the Medicine Maker Power List in 2017. Additionally, Prof Chas Bountra was chairman in Spinifex SAB for over 7 years, which developed a novel therapeutic for pain, and was purchased by Novartis for $700M USD in June 2015.
His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, pre-competitively ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of SGC science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery.
He has received funding for multiple structural Genomics Phases from the likes of GSK, Pfizer, Lilly, Takeda, Abbvie and Merck for over $100M USD. He has given over 300 invited lectures. In 2012 he was voted one of the “top innovators in the industry”.
Michael Moore is a preeminent immunologist, who began his career at the Paterson Institute for Cancer Research and Manchester University, where he was Reader in Experimental Oncology and Immunology and sometime Editor-in Chief of the British Journal of Cancer.
He entered the UK biotechnology industry in 1989, subsequently becoming a director of Xenova Group, which went public on NASDAQ (1994) and LSE (1996). He facilitated the divestment of the Group’s drug discovery division, assisted in the consolidation of Xenova as an oncology-focused business and played a major role in the acquisition and integration of the biologics company Cantab Pharmaceuticals (2000) in the capacity of Chief Scientific Officer.
IIn 2002, Dr Moore became Chief Executive Officer of Piramed Limited, a private UK-based biotechnology company dedicated to the discovery and development of small molecule inhibitors of PI 3-kinases. Piramed is credited with bringing this new class of drug to clinical trial on behalf of Cancer Research UK, the Institute of Cancer Research and the Ludwig Institute for Cancer Research. Piramed entered into collaboration with Genentech in 2005 with a headline valuation of $230 million and was subsequently acquired by Roche in 2008.
Dr Moore practises as a biopharmaceutical consultant and business angel with a portfolio of non-executive directorships, including Chairman of Trillium Therapeutics Inc., a private Toronto-based biologics company, Myotec, a speciality pharma company spun out of Imperial College London and Charité University, Berlin and Oxford BioTherapeutics, a cancer antibody therapy-based company. He is also a Associate Professor in the Department of Cancer Genetics and Pharmacogenomics in the Brunel Institute.
Sallie Lamb is a Professor of Trauma Rehabilitation at the University of Oxford and the Director of the Oxford Clinical Trials Research Unit. She is also Director of the Centre for Statistics in Medicine and a Professor of Rehabilitation at the University of Warwick. Prof Sallie Lamb was awarded an MSc in Rehabilitation with Distinction from Southampton University in 1991, and subsequently awarded the PPP Research Fellowship in Healthcare of Older People at the University of Oxford in 1991, where she completed a doctoral study of mobility limitation in frail older people under the supervision of eminent gerontologist, Professor Sir John Grimley Evans.
Her interests in gerontology span understanding physiological mechanisms of mobility limitation, frailty and falls in older people, to developing interventions that can be applied to improve quality of life and function of older people who have multiple co-morbidities and cognitive impairments. These include exercise interventions to target the geriatric syndromes (falls, frailty, incontinence and depression), multi-factorial interventions for the prevention of falls and fractures, minimally invasive approaches to the management of severe injury and fracture in older people, interventions for osteoarthritis, rheumatoid arthritis and back pain, and studies to improve field testing and diagnosis of gait and mobility problems in older people.
Anne Cooke is a British biologist and academic, specialising in immunology and autoimmune diseases. From 2000 to 2013, she was Professor of Immunobiology at the University of Cambridge. She was also a Fellow of King’s College, Cambridge between 1992 and 2013. Currently, Prof Cooke is an Emeritus Professor of Immunology at the University of Cambridge.
Prof Cooke’s research interests include stem cells and tissue regulation as well as immunology. Her studies have largely focused on Type 1 diabetes. In this autoimmune disease the insulin producing pancreatic ß cells are destroyed by the immune system. When an individual develops symptoms of Type 1 diabetes they have already destroyed many of their ß cells (70%). An ideal therapeutic approach would therefore be to permanently halt the autoimmune attack (develop immune tolerance) while preserving the ability to fight infection and also to facilitate the replacement of the destroyed ß cells.
Prof Cooke has over 6 key publications in her field.
Anne Schafer is Associate Professor of Medicine and of Epidemiology & Biostatistics at UCSF and a practicing endocrinologist at the San Francisco VA Medical Centre. She is board-certified by the American Board of Internal Medicine in the subspecialty of Endocrinology, Diabetes and Metabolism. Her research focus is osteoporosis and bone metabolism. One of her research emphases is osteoporosis treatment and the assessment of response to osteoporosis therapy. She also studies the relationships between bone, fat, and glucose metabolism, including the effects of obesity and diabetes on bone, and the skeletal regulation of energy metabolism.
Currently, Prof Schafer is investigating the effects of bariatric surgery (weight loss surgery) on calcium metabolism and skeletal health. Prof Schafer’s research has been funded by the NIH (National Institute of Diabetes and Digestive and Kidney Diseases), the US Department of Veterans Affairs, and the American Society for Bone and Mineral Research.
Glenn Larsen has more than 30 years of scientific and executive management experience in pharmaceutical, biotech, orthopedics and regenerative medicine. Dr Larsen joined Hydra from Wyeth Pharmaceuticals, where he served as Vice President of Musculoskeletal Sciences, directing R&D for Wyeth’s second largest therapeutic area in the fields of arthritis, inflammation and tissue regeneration. He co-chaired of Musculoskeletal Therapeutic Area, responsible for directing Wyeth’s global commercial and development efforts. Prior to Wyeth’s acquisition of American Home Products – Genetics Institute, he served as Vice President of Preclinical Research and Development of Genetics Institute.
He started his career with Genetics Institute, where he served in variety of leadership positions in drug discovery, program management and drug development. Dr. Larsen serves on the Board of Directors of Aquinnah Pharmaceuticals, Inc. He has been an Independent Director of Anika Therapeutics Inc. since February 2015. He also served as Director of Hydra Biosciences, Inc. Dr. Larsen received his Ph.D. in Biochemistry from the State University of New York at Stony Brook and is a graduate of Harvard University’s Business School PMD program.
Previously, Dr Larsen was the Vice President of Musculoskeletal Sciences at Wyeth, which was acquired by Pfizer for $68B. Dr Larsen was responsible for directing the R&D of Enbrel, an anti-TNF therapeutic, which Amgen later acquired in a $16B USD acquisition of Immunex.